Azithromycin to Prevent Pertussis in Household Contacts, Catalonia and Navarre, Spain, 2012-2013


Por: Alvarez, J, Godoy, P, Plans-Rubio, P, Camps, N, Carol, M, Carmona, G, Solano, R, Rius, C, Minguell, S, Barrabeig, I, Sala-Farre, MR, Rodriguez, R, Garcia-Cenoz, M, Munoz-Almagro, C, Dominguez, A

Publicada: 1 nov 2020
Resumen:
We retrospectively assessed the effectiveness of azithromycin in preventing transmission of pertussis to a patient's household contacts. We also considered the duration between symptom onset in the primary patient and azithromycin administration. We categorized contacts into 4 groups: those treated within <= 7 days, 8-14 days, 15-21 days, and >21 days after illness onset in the primary patient. We studied 476 primary index patients and their 1,975 household contacts, of whom 4.5% were later identified as having pertussis. When contacts started chemoprophylaxis within <= 21 days after the primary patient's symptom onset, the treatment was 43.9% effective. Chemoprophylaxis started >14 days after primary patient's symptom onset was less effective. We recommend that contacts of persons with pertussis begin chemoprophylaxis within <= 14 days after primary patient's symptom onset.

Filiaciones:
Alvarez, J:
 Agencia Salut Publ Catalunya, Barcelona, Spain

Godoy, P:
 Agencia Salut Publ Catalunya, Barcelona, Spain

 Inst Recerca Biomed Lleida, Lleida, Spain

 Consorcio Invest Biomed Red Epidemiol & Salud Pub, Madrid, Spain

Plans-Rubio, P:
 Agencia Salut Publ Catalunya, Barcelona, Spain

 Consorcio Invest Biomed Red Epidemiol & Salud Pub, Madrid, Spain

Camps, N:
 Agencia Salut Publ Catalunya, Barcelona, Spain

Carol, M:
 Agencia Salut Publ Catalunya, Barcelona, Spain

Carmona, G:
 Agencia Salut Publ Catalunya, Barcelona, Spain

Solano, R:
 Consorcio Invest Biomed Red Epidemiol & Salud Pub, Madrid, Spain

 Agencia Salut Publ Barcelona, Barcelona, Spain

Rius, C:
 Consorcio Invest Biomed Red Epidemiol & Salud Pub, Madrid, Spain

 Agencia Salut Publ Barcelona, Barcelona, Spain

Minguell, S:
 Agencia Salut Publ Catalunya, Barcelona, Spain

Barrabeig, I:
 Agencia Salut Publ Catalunya, Barcelona, Spain

 Consorcio Invest Biomed Red Epidemiol & Salud Pub, Madrid, Spain

Sala-Farre, MR:
 Agencia Salut Publ Catalunya, Barcelona, Spain

Rodriguez, R:
 Agencia Salut Publ Catalunya, Barcelona, Spain

Garcia-Cenoz, M:
 Consorcio Invest Biomed Red Epidemiol & Salud Pub, Madrid, Spain

 Inst Salud Publ Navarra, Pamplona, Spain

Munoz-Almagro, C:
 Consorcio Invest Biomed Red Epidemiol & Salud Pub, Madrid, Spain

 Hosp St Joan Deu, Barcelona, Spain

Dominguez, A:
 Consorcio Invest Biomed Red Epidemiol & Salud Pub, Madrid, Spain

 Univ Barcelona, Barcelona, Spain
ISSN: 10806040





EMERGING INFECTIOUS DISEASES
Editorial
CENTERS DISEASE CONTROL & PREVENTION, 1600 CLIFTON RD, ATLANTA, GA 30333 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 26 Número: 11
Páginas: 2678-2684
WOS Id: 000596803200016
ID de PubMed: 33079034
imagen gold, Green Published

MÉTRICAS